ADVERTISEMENT
  About the SA Blog Network













Guest Blog

Guest Blog


Commentary invited by editors of Scientific American
Guest Blog HomeAboutContact

Personalizing cancer medicine

The views expressed are those of the author and are not necessarily those of Scientific American.


Email   PrintPrint



Over 1.5 million new cancer cases were identified in the United States in 2010, and despite continued advances in cancer treatment, approximately 500,000 cancer-related deaths occurred in the same year (1). For a long time, cancer therapies were a one-size-fits-all, depending on the cancer type. In recent years however, the need has emerged to develop a more enlightened paradigm in which treatments are better tailored towards the individual uniqueness of the cancer (2).

Personalized Medicine is a catch phrase that reflects the current understanding that no two patients are alike. The primary goal of personalized medicine is to develop patient-specific treatments that can hopefully reduce unnecessary side effects as well as the overall cost of cancer care by using therapies that are most likely to be effective in the population that is most likely to benefit (3).

The field of personalized medicine is rapidly expanding and Targeted Therapies are the cornerstone of the personalized medicine revolution. Targeted therapies are drugs that block the growth and spread of cancer by interfering with specific molecules involved in tumor growth and progression and as such, may be more effective than other types of treatment, including chemotherapy and radiotherapy, and less harmful to normal cells (4).

According to the National Cancer Institute (NCI), many targeted cancer therapies have been approved by the U.S. Food and Drug Administration (FDA) while others are being studied in clinical trials. Some key examples of classes of agents include (4):

* Signal transduction inhibitors, which block specific enzymes and growth factor receptors involved in cancer cell proliferation

* Modifiers of proteins that regulate gene expression and other cellular functions

* Inducers of apoptosis

* Inhibitors of tumor blood vessel growth

* Monoclonal antibodies that deliver toxic molecules to cancer cells

* Cancer vaccines and gene therapy

 

Nevertheless, targeted therapies have some limitations. Chief among these is the potential for cells to develop resistance. As a result, targeted therapies may work best in combination, either with other targeted therapies or with more traditional therapies (4).

Cancer is a complex genetic disease and as more is learned about the genetic mechanics of cancer growth, the hope is that this knowledge will be leveraged to identify new molecular diagnostics and provide new strategies for tailoring therapies to fit the needs of each cancer patient’s unique biology.

Bibliography:

1. CA Cancer J Clin. 2010 Sep–Oct;60(5):277-300

2. http://www.lef.org/magazine/mag2010/apr2010_Cancer-Treatment-Utilizing-Advanced-CTC-Molecular-Analysis_01.htm

3. Sonali Smith, MD, ASCO Annual Meeting 2009

4. http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted

About the Author: Karen Ventii, PhD, is a medical writer based in Atlanta, Ga.

The views expressed are those of the author and are not necessarily those of Scientific American.

Tags:






Comments 2 Comments

Add Comment
  1. 1. barfalo 11:59 am 02/7/2011

    For all the money spent on bailouts and wars, it’s a shame we can’t spend a much smaller amount to radically advance cancer treatments. Avax Technologies(AVXT.PK)has a vaccine made from the patients own cancer cells that, at a minimum, doubles the the success rates for melanoma, ovarian cancer, and even shows great promise on lung cancer. They’ve made it through phase I/II clinical trails showing great results but can’t find the $30-50 million dollars to fund Phase III trials. Theyve already spent more than $130 million on developing the drug, have made deals with the FDA for accelerated approval and orphan drug status but now looks like they will have to close the doors because of lack of funding. I don’t understand how the "wizards of the world" can spend trillions saving the banks and oil companies so they can make record profits off of us, but refuse to scrape together $50 million dollars to save millionsand millions of people and families from this terrible disease. This is a disgraceful world.

    Link to this
  2. 2. bucketofsquid 5:30 pm 02/10/2011

    While I know nothing about the specific company you identify, I also feel that we are being cheated by the greed mongers and left to wither and die when even modest medical research investments by the feds can save or extend millions of lives. The longer a person is alive and able to work the more they contribute to the economy. It is just good economics to have a long lived, health population.

    Link to this

Add a Comment
You must sign in or register as a ScientificAmerican.com member to submit a comment.

More from Scientific American

Scientific American Special Universe

Get the latest Special Collector's edition

Secrets of the Universe: Past, Present, Future

Order Now >

X

Email this Article

X